98%
921
2 minutes
20
Background : Diabetic ketoacidosis (DKA) is a life-threatening emergency. Microvascular hyporeactivity has been reported in these patients and is completely reversible when acidosis is corrected with aggressive treatment. The shape of the red blood cell (RBC), a sensor of local hypoxia and a component of the microcirculation, is altered in diabetic patients, but no data are available concerning RBC deformability in DKA during treatment. Methods : In this prospective observational study, we included all adult patients admitted with DKA to a 32-bed medico-surgical intensive care unit (ICU) over a 6-month period. We excluded patients with infection. We measured RBC deformability in the DKA patients and compared results with those from patients with type 1 diabetes and from a group of healthy volunteers (HV). RBC deformability was assessed using ektacytometry. In the DKA patients, it was assessed at ICU admission, 8 and 24 h after admission, and prior to ICU discharge (48-72 h). The RBC elongation index (EI) was determined based on the laser diffraction pattern changes. A higher EI indicates greater RBC deformability. Results : A total of 46 diabetic patients (15 DKA and 31 type 1 diabetes patients) and 20 HV were included. RBC deformability was more altered at ICU admission in DKA patients, with significantly lower EI values than in the other groups, and these alterations persisted during the ICU stay despite treatment. There were no correlations between these alterations and the quantity of fluids or insulin received. Conclusions : In contrast to the reversible microvascular hyporeactivity observed in DKA, RBC deformability was already altered at ICU admission in patients with DKA and remained altered despite treatment. These alterations may contribute to the blood flow abnormalities observed in these patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/SHK.0000000000002572 | DOI Listing |
Clin Hemorheol Microcirc
September 2025
Department of Internal Medicine, Sultan Abdülhamid Han Research & Training Hospital, University of Health Sciences, Istanbul, Turkey.
ObjectivesThis study investigated haemorheological alterations in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).MethodsA total of 136 individuals were enrolled, comprising 52 healthy controls, 51 RA patients, and 33 SLE patients. Blood samples were collected at the University of Health Sciences Sultan Abdulhamid Han Training and Research Hospital in Istanbul, Türkiye.
View Article and Find Full Text PDFFront Med (Lausanne)
August 2025
Department of Zoology, Biomedical Technology, Human Genetics & Wildlife Biology and Conservation, School of Sciences, Gujarat University, Ahmedabad, India.
Extracellular vesicles (EVs) offer promising opportunities in hematology for improved diagnostics, prognostics, and therapeutics, making them valuable tools in the molecular landscape. EVs derived from red blood cells (RBCs) are the primary source of EVs in the bloodstream. They perform several critical biological and physiological functions, such as facilitating intercellular communication and transferring biomolecules like DNA, RNA, and proteins.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
September 2025
Department of Physical Examination Center, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Background: The aging problem is a significant issue and challenge currently faced by the whole world. Hyperhomocysteinemia (HHcy) is a common phenomenon among the older adult. Increasing evidence suggests a link between HHcy and multiple systemic issues in the older adult-related diseases.
View Article and Find Full Text PDFClin Pharmacol Ther
September 2025
Pfizer Inc, New York, New York, USA.
The investigational agent osivelotor, a small molecule hemoglobin (Hb) modifier in development for the treatment of sickle cell disease (SCD), acts by increasing Hb-oxygen affinity and inhibiting the polymerization of sickle Hb. We report safety, pharmacokinetic (PK), and pharmacodynamic (PD) data from the first two phase 1 clinical trials of osivelotor in healthy participants and participants with SCD. Healthy participants (N = 129) were randomized to receive either osivelotor or placebo in single-ascending doses (50-3,000 mg) or multiple-ascending doses (loading doses, then 15-100 mg once-daily maintenance doses through 14 days).
View Article and Find Full Text PDFMicromachines (Basel)
August 2025
Shenzhen Bay Laboratory, Institute of Biomedical Engineering, Shenzhen 518107, China.
The deformability of red blood cells (RBCs) is critical for microvascular circulation and is impaired in hematological disorders such as thalassemia, a prevalent public health concern in Guangdong, China. While microfluidics enable high-precision deformability assessment, current studies lack standardization in deformation metrics and rarely investigate post-deformation recovery dynamics. This study introduces an automated microfluidic platform for systematically evaluating RBC deformability in healthy and thalassemic individuals.
View Article and Find Full Text PDF